TY - JOUR
T1 - Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content
AU - Dobbs, Kerry
AU - Tabellini, Giovanna
AU - Calzoni, Enrica
AU - Patrizi, Ornella
AU - Martinez, Paula
AU - Giliani, Silvia Clara
AU - Moratto, Daniele
AU - Al-Herz, Waleed
AU - Cancrini, Caterina
AU - Cowan, Morton J.
AU - Bleesing, Jacob
AU - Booth, Claire
AU - Buchbinder, David K.
AU - Burns, Siobhan O
AU - Chatila, Talal A
AU - Chou, Janet
AU - Daza-Cajigal, Vanessa
AU - Ott de Bruin, Lisa M
AU - de la Morena, MaiteTeresa
AU - Di Matteo, Gigliola
AU - Finocchi, Andrea
AU - Geha, Raif S.
AU - Goyal, Rakesh K
AU - Hayward, Anthony
AU - Holland, Steven M.
AU - Huang, Chiung-Hui
AU - Kanariou, Maria G
AU - King, Alejandra
AU - Kaplan, Blanka
AU - Kleva, Anastasiya
AU - Kuijpers, Taco W.
AU - Lee, Bee Wah
AU - Lougaris, Vassilios
AU - Massaad, Michel
AU - Meyts, Isabelle
AU - Morsheimer, Megan
AU - Neven, Benedicte
AU - Pai, Sung-Yun
AU - Plebani, Alessandro
AU - Prockop, Susan
AU - Reisli, Ismail
AU - Soh, Jian Yi
AU - Somech, Raz
AU - Torgerson, Troy R
AU - Kim, Yae-Jaen
AU - Walter, Jolan E
AU - Gennery, Andrew R.
AU - Keles, Sevgi
AU - Manis, John P
AU - Marcenaro, Emanuela
AU - Moretta, Alessandro
AU - Parolini, Silvia
AU - Notarangelo, Luigi D
N1 - Publisher Copyright:
© 2017 Dobbs, Tabellini, Calzoni, Patrizi, Martinez, et al.
PY - 2017
Y1 - 2017
N2 - Mutations of the recombinase-activating genes 1 and 2 (RAG1 and RAG2) in humans are associated with a broad range of phenotypes. For patients with severe clinical presentation, hematopoietic stem cell transplantation (HSCT) represents the only curative treatment; however, high rates of graft failure and incomplete immune reconstitution have been observed, especially after unconditioned haploidentical transplantation. Studies in mice have shown that Rag-/- natural killer (NK) cells have a mature phenotype, reduced fitness, and increased cytotoxicity. We aimed to analyze NK cell phenotype and function in patients with mutations in RAG and in non-homologous end joining (NHEJ) genes. Here, we provide evidence that NK cells from these patients have an immature phenotype, with significant expansion of CD56bright CD16-/int CD57- cells, yet increased degranulation and high perforin content. Correlation was observed between in vitro recombinase activity of the mutant proteins, NK cell abnormalities, and in vivo clinical phenotype. Addition of serotherapy in the conditioning regimen, with the aim of depleting the autologous NK cell compartment, may be important to facilitate engraftment and immune reconstitution in patients with RAG and NHEJ defects treated by HSCT.
AB - Mutations of the recombinase-activating genes 1 and 2 (RAG1 and RAG2) in humans are associated with a broad range of phenotypes. For patients with severe clinical presentation, hematopoietic stem cell transplantation (HSCT) represents the only curative treatment; however, high rates of graft failure and incomplete immune reconstitution have been observed, especially after unconditioned haploidentical transplantation. Studies in mice have shown that Rag-/- natural killer (NK) cells have a mature phenotype, reduced fitness, and increased cytotoxicity. We aimed to analyze NK cell phenotype and function in patients with mutations in RAG and in non-homologous end joining (NHEJ) genes. Here, we provide evidence that NK cells from these patients have an immature phenotype, with significant expansion of CD56bright CD16-/int CD57- cells, yet increased degranulation and high perforin content. Correlation was observed between in vitro recombinase activity of the mutant proteins, NK cell abnormalities, and in vivo clinical phenotype. Addition of serotherapy in the conditioning regimen, with the aim of depleting the autologous NK cell compartment, may be important to facilitate engraftment and immune reconstitution in patients with RAG and NHEJ defects treated by HSCT.
KW - CD56
KW - Degranulation
KW - Immunodeficiency
KW - Interferon-γ
KW - Natural killer cells
KW - Non-homologous end joining
KW - Recombinase-activating genes
UR - http://www.scopus.com/inward/record.url?scp=85025431730&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2017.00798
DO - 10.3389/fimmu.2017.00798
M3 - Article
C2 - 28769923
SN - 1664-3224
VL - 8
JO - Frontiers in Immunology [E]
JF - Frontiers in Immunology [E]
IS - JUL
M1 - 798
ER -